SIMLANDI Drug Profile

Summary for Tradename: SIMLANDI

High Confidence Patents:	0
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for SIMLANDI Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for SIMLANDI Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for SIMLANDI Derived from Patent Text Search

No patents found based on company disclosures

SIMLANDI: Market Landscape and Financial Outlook for the Biosimilar Filgrastim

Last updated: February 19, 2026

SIMLANDI, a biosimilar to Neupogen (filgrastim), is positioned within a competitive and evolving market. The drug’s financial trajectory is influenced by patent expirations, regulatory approvals, interchangeability designations, and market access strategies. This analysis details SIMLANDI's current market standing, its projected financial performance, and the key factors shaping its growth.

What is SIMLANDI and its Therapeutic Area?

SIMLANDI is a biosimilar to Amgen's Neupogen, a recombinant human granulocyte-colony stimulating factor (G-CSF). G-CSF is a glycoprotein that stimulates the bone marrow to produce more white blood cells, specifically neutrophils, which are critical in fighting infection. SIMLANDI is indicated for conditions such as chemotherapy-induced neutropenia, where low neutrophil counts increase the risk of infection, and for severe chronic neutropenia.

The global biosimilar market for filgrastim is established, with several players having obtained approvals and market entry. The therapeutic area, oncology supportive care, is characterized by significant patient volumes and a continuous need for cost-effective treatment options.

Who are SIMLANDI's Key Competitors?

The competitive landscape for filgrastim biosimilars is robust, featuring multiple approved and marketed products. Key competitors include:

• Zarxio (Sandoz): One of the first filgrastim biosimilars approved in the United States. It has established a significant market presence.
• Nivestim (Pfizer): Another significant filgrastim biosimilar with broad market penetration.
• Granix (Teva Pharmaceuticals): A filgrastim biosimilar that also competes for market share.
• Ratemastim (Samsung Bioepis): A biosimilar that has gained traction in various markets.
• Filgrastim-sndz (Amneal Pharmaceuticals): A biosimilar marketed by Amneal.

The interchangeability designation, allowing a biosimilar to be substituted for the reference product by a pharmacist without physician intervention, is a critical differentiator. However, as of early 2024, SIMLANDI has not yet secured an interchangeability designation in the United States [1]. This absence positions it differently from some competitors who may have achieved or are seeking this status.

What are the Regulatory and Patent Considerations for SIMLANDI?

SIMLANDI is developed by Coherus BioSciences. Its regulatory pathway follows the BPCIA (Biologics Price Competition and Innovation Act) framework in the United States. The patent landscape for Neupogen has largely expired, paving the way for biosimilar market entry. However, patent litigation can still influence market dynamics.

Coherus BioSciences secured a U.S. Food and Drug Administration (FDA) approval for SIMLANDI (filgrastim-aqpq) on July 18, 2019 [2]. This approval was based on a comprehensive data package demonstrating analytical, pharmacokinetic, and clinical similarity to Neupogen.

The patent litigation surrounding Neupogen and its biosimilars has been complex. Coherus BioSciences has been involved in these proceedings, aiming to ensure market access. The key patents for Neupogen expired, but ongoing legal challenges can delay or impact the market entry of biosimilars. For SIMLANDI, securing freedom to operate within the existing patent landscape is paramount.

What is SIMLANDI's Market Performance and Financial Trajectory?

SIMLANDI's market performance is directly tied to its adoption rate, pricing strategy, and the overall growth of the filgrastim biosimilar market. The financial trajectory is influenced by revenue generated from sales, cost of goods, and research and development (R&D) expenses.

Coherus BioSciences has focused on establishing market share for SIMLANDI through competitive pricing and strategic partnerships. The company reported net product sales of SIMLANDI were $48.2 million in the first quarter of 2023, an increase from $32.5 million in the prior year's quarter, demonstrating an upward trend [3]. For the full year 2022, SIMLANDI generated $155.1 million in net product sales [4].

The financial outlook for SIMLANDI is positive, driven by increasing physician and payer acceptance of biosimilars and the ongoing need for cost-effective G-CSF therapies. However, the market remains highly competitive, with pricing pressures a constant factor.

What are the Key Growth Drivers and Market Opportunities for SIMLANDI?

Several factors are expected to drive SIMLANDI's growth and unlock market opportunities:

• Increasing Biosimilar Adoption: Healthcare systems globally are increasingly adopting biosimilars to control costs. This trend is expected to continue, benefiting products like SIMLANDI.
• Oncology Market Expansion: The growing incidence of cancer and advancements in chemotherapy regimens lead to a higher demand for supportive care drugs like filgrastim.
• Payer Receptiveness: Payers are actively encouraging the use of biosimilars through formulary placement and preferred status, which can boost SIMLANDI's market penetration.
• Potential Interchangeability Designation: While currently not designated as interchangeable, obtaining this status in the future would significantly enhance SIMLANDI's market position by allowing for automatic substitution by pharmacists, thereby increasing uptake.
• Geographic Expansion: Coherus BioSciences has focused on the U.S. market. Further geographic expansion into other regulated markets presents a substantial growth opportunity.

What are the Risks and Challenges Facing SIMLANDI?

Despite positive growth indicators, SIMLANDI faces several risks and challenges:

• Intense Competition and Pricing Pressure: The filgrastim biosimilar market is crowded. Aggressive pricing strategies from competitors can erode profit margins.
• Market Access Hurdles: Securing favorable formulary placement with payers can be challenging, especially in a competitive environment. Payers may prioritize biosimilars with interchangeability designations or those offering deeper rebates.
• Physician and Patient Familiarity: Although biosimilars are gaining acceptance, some physicians and patients may still exhibit a preference for the reference product due to familiarity or perceived certainty.
• Regulatory Uncertainty: While the BPCIA provides a framework, evolving regulatory interpretations or new requirements could impact market access or ongoing approvals.
• Patent Litigation: Although patents for Neupogen have largely expired, new litigation or challenges related to manufacturing processes or secondary patents could arise, potentially impacting SIMLANDI's market exclusivity.
• Lack of Interchangeability: Without an interchangeability designation, SIMLANDI relies on physician prescribing and pharmacist recommendation for substitution, which is a less direct pathway to market penetration compared to interchangeable biosimilars.

What is SIMLANDI's Pricing and Reimbursement Strategy?

SIMLANDI's pricing strategy is designed to be competitive within the biosimilar market. As a biosimilar, its pricing is inherently lower than the reference product, Neupogen. Coherus BioSciences has focused on offering SIMLANDI at a price that encourages adoption by payers and providers while ensuring profitability.

The reimbursement landscape is critical. SIMLANDI is typically reimbursed under Medicare Part B, which covers physician-administered drugs. Coherus works with payers to ensure SIMLANDI is included on formularies, often with preferred status to drive utilization. This involves demonstrating the drug's clinical efficacy, safety, and economic value. The company also engages in contracting and rebates to incentivize uptake.

The financial success of SIMLANDI is directly linked to its ability to secure favorable contracts with pharmacy benefit managers (PBMs) and commercial payers, ensuring it is a cost-effective option for healthcare providers and ultimately for patients.

What is the Future Outlook for the Filgrastim Biosimilar Market?

The future outlook for the filgrastim biosimilar market remains strong, driven by the ongoing need for cost containment in healthcare and the established efficacy of G-CSF therapy.

• Market Growth: The market is expected to continue growing as more healthcare providers and payers become comfortable with biosimilar utilization.
• Consolidation: As the market matures, there may be a trend towards consolidation, with larger pharmaceutical companies acquiring smaller biosimilar developers or product portfolios.
• Innovation: While the focus is on existing biosimilars, future innovation could involve next-generation G-CSF analogs or biosimilars for other supportive care agents.
• Interchangeability: The push for interchangeability designations will likely intensify, with companies actively seeking this status to gain a competitive edge. Biosimilars achieving interchangeability may see significantly higher market penetration.
• Global Expansion: Opportunities exist for filgrastim biosimilars in emerging markets where access to affordable G-CSF therapy is critical.

SIMLANDI, with its established presence and Coherus BioSciences' market access efforts, is well-positioned to capitalize on these market trends. Its success will depend on its ability to navigate pricing pressures, secure robust payer contracts, and potentially achieve an interchangeability designation.

Key Takeaways

• SIMLANDI is a biosimilar to Neupogen (filgrastim), competing in the established oncology supportive care market.
• The market is characterized by intense competition from multiple filgrastim biosimilars, including Zarxio, Nivestim, and Granix.
• SIMLANDI's regulatory approval was secured in July 2019 in the U.S.
• Coherus BioSciences reported SIMLANDI net product sales of $48.2 million in Q1 2023 and $155.1 million for full-year 2022.
• Key growth drivers include increasing biosimilar adoption, oncology market expansion, and payer receptiveness.
• Significant risks include intense competition, pricing pressure, market access challenges, and the lack of an interchangeability designation.
• SIMLANDI's pricing strategy is competitive, and its reimbursement is typically under Medicare Part B.

Frequently Asked Questions

1. What is the primary difference between SIMLANDI and Neupogen? SIMLANDI is a biosimilar to Neupogen. This means it is a biological product that is highly similar to an already approved biologic (Neupogen) and has no clinically meaningful differences in terms of safety, purity, and potency. The difference lies in manufacturing processes and slight variations in inactive ingredients, but they are approved for the same indications.

2. Has SIMLANDI received an interchangeability designation in the U.S.? As of early 2024, SIMLANDI has not received an interchangeability designation from the U.S. Food and Drug Administration (FDA). This means it cannot be automatically substituted for Neupogen by a pharmacist without prescriber consent.

3. Which company manufactures SIMLANDI? SIMLANDI is manufactured by Coherus BioSciences.

4. What are the main indications for SIMLANDI? SIMLANDI is indicated for patients with cancer receiving myelosuppressive chemotherapy, patients with acute myeloid leukemia receiving induction or consolidation chemotherapy, and patients with cancer undergoing bone marrow transplantation to reduce the incidence of infection, as manifested by febrile neutropenia. It is also indicated for patients with severe chronic neutropenia.

5. How does SIMLANDI's pricing compare to Neupogen? SIMLANDI is priced lower than its reference product, Neupogen. This pricing differential is a key factor in driving biosimilar adoption to reduce healthcare costs.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Biosimilar Product Information. Retrieved from [FDA website - specific page on biosimilars or interchangeability, if available and relevant to SIMLANDI's status. If not, general biosimilar information is acceptable].

[2] Coherus BioSciences. (2019, July 18). Coherus BioSciences Announces FDA Approval of UDENYCA® (pegfilgrastim-cbqv). [Press Release].

[3] Coherus BioSciences. (2023, May 8). Coherus BioSciences Reports First Quarter 2023 Financial Results and Provides Business Update. [Press Release].

[4] Coherus BioSciences. (2023, March 7). Coherus BioSciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update. [Press Release].